- Amarin Board of Directors Announces CEO Transition
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
- Amarin Reports First Quarter 2024 Business Update and Financial Results
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
- Amarin Announces Results of Annual General Meeting of Shareholders
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
More ▼
Key statistics
As of last trade Amarin Corporation PLC (EH3A:FRA) traded at 0.585, 3.54% above its 52-week low of 0.565, set on Nov 03, 2023.
52-week range
Open | 0.585 |
---|---|
High | 0.585 |
Low | 0.585 |
Bid | 0.585 |
Offer | 0.685 |
Previous close | 0.585 |
Average volume | 1.53k |
---|---|
Shares outstanding | 410.87m |
Free float | 381.31m |
P/E (TTM) | -- |
Market cap | 282.02m USD |
EPS (TTM) | -0.1288 USD |
Data delayed at least 15 minutes, as of Jul 04 2024 08:09 BST.
More ▼